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Studies have shown that CpG oligodeoxyribonucleotides (ODN) protect mice from various bacterial pathogens,
including Burkholderia pseudomallei and Francisella tularensis live vaccine strain (LVS), when administered before
parenteral challenge. Given the potential to develop CpG ODN as a pre-treatment for multiple bacterial biological
warfare agents, we examined survival, histopathology, and cytokine data from CpG ODN-treated C57BL/6 mice to
determine whether previously-reported protection extended to aerosolized B. pseudomallei 1026b and highly viru-
lent F. tularensis Schu S4 infections. We found that, although CpG ODN protected mice from aerosolized B. pseudo-
mallei challenges, the immunostimulant failed to benefit the animals exposed to F. tularensis Schu S4 aerosols. Our
results, which contrast with earlier F. tularensis LVS studies, highlight potential differences in Francisella species
pathogenesis and underscore the need to evaluate immunotherapies against human pathogenic species.
Findings
Bacteria-derived CpG oligodeoxyribonucleotides (ODN)
are potent stimulators of the innate immune system,
acting via the toll-like receptor (TLR) 9 signaling path-
way. Consequently, the small CpG-rich motifs [1] have
been successfully developed as adjuvants for a broad
array of bacterial subunit vaccines and are currently
undergoing multiple clinical trials [2]. CpG ODNs have
also been administered alone as pretreatments to effec-
tively protect mice from infection by different bacterial
pathogens [3], including the biological warfare threat
agents Burkholderia mallei [4] and Burkholderia pseudo-
mallei [5]. Murine studies of the Francisella tularensis
live vaccine strain (LVS) [3] suggest that CpG ODN
may also protect against human-virulent F. tularensis
Schu S4 infection. Significantly, researchers have shown
that CpG ODNs protect mice from F. tularensis LVS
when the therapy is administered anywhere from two
days to two weeks before parenteral challenge [3] and
can maintain this protection indefinitely when CpG
ODN is given two to three times a month [6]. Provided
CpG ODNs can broadly protect against different aeroso-
lized biological warfare agents days or weeks after treat-
ment, the molecules may represent potential
pretreatments for military or civilian personnel at risk of
exposure to the weaponized bacteria.
In order to determine whether CpG ODN protects
mice from aerosolized B. pseudomallei 1026b or F.
tularensis Schu S4 challenges (all previous reports deal
with parenteral challenges), we gave groups of 8-10
anaesthetized 8-week-old female C57BL6/J mice 20 μli .
n. or 200 μl i.p. injections of Hank’s basal salt solution
(HBSS) 48 h before or 1 h after receiving aerosolized
doses of B. pseudomallei 1026b or F. tularensis Schu S4.
Depending on the group, 150 μg CpG ODN 10103
(Coley Pharmaceutical Group: 5’-TCG TCG TTT CGT
CGT TTT GTC GTT-3’), which has been developed as
a potent stimulant for the human immune system, was
added to the saline treatment. CpG ODN variants are
known to produce different immunostimulatory
responses in different mammalian species [7]. However,
our own unpublished studies suggest that CpG ODN
10103 performs comparably in mice to CpG ODN 7909
(5’-TCGTCGTTTTGTCGTTTTGTCGTT-3’), which
w a sp r e v i o u s l yr e p o r t e dt op r o t e c tt h eB A L B / cm i c e
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ODN 10103’s traditional use as a human adjuvant, we
have found that the immunostimulant’s ability to protect
mice from aerosolized B. pseudomallei (reported here)
and B. mallei (unpublished data) suggest that, as with
the CpG motifs used in other Burkholderia and F. tular-
ensis murine studies [3-6], the oligodeoxyribonucleotide
is an effective immunostimulant in both C57BL6/J and
BALB/c mice.
We gave saline control and CpG ODN 10103-treated
mice different aerosolized doses of B. pseudomallei
1026b or F. tularensis Schu S4 prepared from 37°C
overnight glycerol tryptone broth or IsoVitaleX (BD
Diagnostic Systems, Sparks, MD)-supplemented Mueller
Hinton broth cultures, respectively. Serial dilutions of
nebulizer and impinger medium were prepared in tripli-
cate and spread on solid media to calculate actual
inhaled doses. When necessary, mice from each treat-
ment group were split evenly between consecutive aero-
sol runs to accommodate potential variations in aerosol
dose from one run to the next. As indicated in Figure 1,
CpG ODN-treated mice were significantly protected
from high and low doses of aerosolized B. pseudomallei
1026b challenges (p < 0.05 when compared to saline
controls). However this was not the case for F. tularen-
sis Schu S4-infected animals, which were unprotected
regardless of challenge dose or treatment route. In fact,
our data suggests that CpG ODN 10103 therapies may
have adversely affected the survival of F. tularensis-
infected mice. Specifically, mice given 150 μg CpG ODN
i.n. 48 h prior to challenge actually exhibited a statisti-
cally significant (p < 0.025) decrease in survival when
compared to controls. Furthermore, when all mice
receiving 55 cfu aerosolized F. tularensis Schu S4 are
grouped according to whether or not they received CpG
ODN, regardless of treatment route and time, the
untreated controls exhibited a statistically elevated survi-
val curve (p = 0.05). B. pseudomallei and F. tularensis-
infected mice were statistically unaffected by giving the
CpG ODN treatments via different routes (i.n. or i.p.)
and times (48 h before or 1 h after infection).
To further explore the bacterial response to CpG
ODN treatments, we repeated aerosol challenges for
groups of nine mice that had received CpG ODN i.n.
treatments 48 h before infection. Each of the mice
received average inhaled doses of 236 cfu of B. pseudo-
mallei 1026b or 3,100 cfu of Francisella Schu S4. Three
mice from each experimental group were euthanized 1,
3, and 6 days post infection to observe disease progres-
sion in lungs, livers, and spleens. In a qualitative review
of hematoxylin- and eosin-stained, paraffin-embedded
tissues, CpG ODN-treated mice exhibited elevated levels
of hepatitis and interstitial pneumonia at all time points
compared to untreated mice, regardless of whether or
n o tt h e yw e r ec h a l l e n g e dw i t hB. pseudomallei1026b or
F. tularensis Schu S4. The latter observation is consis-
tent with CpG ODN-induced lung inflammation pre-
viously reported for uninfected mice [8]. Whereas CpG
ODN treatment prevented bronchopneumonia, pulmon-
ary abscesses, liver necrosis, and splenic thrombi in B.
pseudomallei 1026b-infected mice 3 and 6 days postin-
fection, the development of pulmonary abscesses and
hepatic and splenic necrosis in F. tularensis Schu S4-
challenged mice remained unaffected by CpG ODN
treatment. Six days postinfection, B. pseudomallei and F.
tularensis infections of untreated mice were typified by
bronchopneumonia and thrombosis in the former and
interstitial pneumonia, hepatitis, and splenic necrosis in
the latter (Figure 2).
T i s s u es a m p l e sf r o mt h es a m em i c ew e r ea l s og r o u n d
and diluted 10-fold by mass into 25 mM pH 7.0 potas-
sium phosphate buffer before aliquots were sampled
using the BD Cytokine Bead Array (CBA) Mouse
Inflammation kit (BD Biosciences, San Jose, CA) accord-
ing to the manufacturer’s protocol. Cytokine levels in
the livers, lungs, and spleens of mice euthanized on days
1, 3, and 6 postinfection correlated well with the B.
pseudomallei-a n dF. tularensis-induced pathogenesis
observed in the same tissue samples (Figure 2). Whereas
interleukin (IL)-6, monocyte chemotactic protein
(MCP)-1, interferon (IFN)-g, and tumor necrosis factor
(TNF) were statistically elevated in the hepatic tissue of
untreated B. pseudomallei-infected mice, the cytokines
dropped to basal levels in the lungs and livers of simi-
larly infected CpG ODN-treated mice, which generally
lacked culturable bacteria at 6 days postinfection. Con-
versely, 6 days after infection, cytokine levels were dra-
matically elevated in the lungs, livers, and spleens of F.
tularensis-challenged mice, regardless of whether or not
they received CpG ODN treatments. Elevated cytokine
levels in the lungs and spleens of F. tularensis-infected
animals 6 days postinfection correlated well with the
recruitment of immune cells to the interstitial lung tis-
sue and acute necrosis of the spleen observed by
histopathology.
The novel aerosol data presented here corroborate
previous reports of CpG ODN-mediated protection for
B. pseudomallei- i n f e c t e dB A L B / cm i c ew i t hn o v e ld a t a
for low- and high-dose aerosolized challenges of
C57BL6/J mice. However, the results of our F. tularensis
Schu S4 experiments contrast with earlier accounts of
the protection offered by CpG ODN treatments for
C57BL6/J mice challenged with the less virulent F.
tularensis LVS. The independent survival and histo-
pathology experiments presented in Figures 1 and 2
reveal that CpG ODN 10103 failed to positively affect
t h ec o u r s eo fF. tularensis Schu S4 pneumonic infection
and statistically reduced the survival rates for CpG
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Page 2 of 5Figure 1 CpG ODN 10103 differently protects mice from aerosolized B. pseudomallei 1026b and F. tularensis Schu S4 challenges.
Groups of 8-10 C57BL6/J mice were given saline (bold solid lines) or 150 μg CpG ODN 10103 via intranasal (bold dashed lines) or
intraperitoneal (thin solid lines) injection 48 h before or 1 h after being challenged with aerosolize B. pseudomallei 1026b or F. tularensis Schu S4
and observed for 14-28 days. The calculated inhaled bacterial doses are given above each graph. Intraperitoneal and 1 h post-challenge
therapies were only administered during the low-dose challenges. Survival curves were compared using log-rank (Mantel-Cox) tests.
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Schu S4 aerosols.
Differing responses to immunostimulatory treatments
have already been reported among Francisella species
and appear to be consistent with the potentially adverse
effects observed here for F. tularensis Schu S4, which is
known to actively impair host immune response [9,10].
Specifically, Kieffer et al reported that mice treated with
either F. tularensis LVS- or F. novicida U112-derived
lipopolysaccaride (LPS) 3-5 days before bacterial chal-
lenge were protected from F. tularensis LVS, but not F.
novicida U112, infections [11]. In fact, the group
observed that their LPS therapies may have actually
enhanced the virulence F. novicida,w h i c hi sm o r ec l o -
sely related by genome analysis [12,13] and murine viru-
lence models [11] to F. tularensis type A strains than
type B. Therefore, while our findings regarding F. tular-
ensis Schu S4 infection in CpG ODN-treated mice are
Figure 2 CpG ODN 10103 administered intranasally 48 h prior to infection differently effects B. pseudomallei 1026b and F. tularensis
Schu S4 pathogenesis in aerosol-challenged mice. At 6 days post infection, mice challenged with B. pseudomallei developed
bronchopneumonia and pulmonary abscesses (A: arrowheads) and areas of liver necrosis (B: arrows). By contrast, B. pseudomallei-infected mice
pretreated with CpG ODN developed only mild interstitial pneumonia (C) and lymphoplasmacytic hepatitis (D: arrows). F. tularensis-challenged
mice exhibited bronchopneumonia and pulmonary abscesses (E, G: arrows) and areas of liver necrosis (F, H: arrows) 6 days after infection
regardless of whether or not they received CpG ODN. Cytokine levels in the livers and lungs of saline (red circles)- and CpG ODN (blue squares)-
treated mice differed significantly for mice infected with B. pseudomallei but not F. tularensis. Mean cytokine levels for tissues obtained from mice
1, 3, and 6 days after infection are rendered as colored bars. Asterisks indicate statistically significant differences (p < 0.05) between saline- and
CpG ODN-treated groups on day 6. Parenthetical values accompanying cytokine labels indicate numbers of independent data points obtained
for saline- and CpG ODN-treated mice. Cytokine concentrations below 1 pg/ml fall below the x-axis and are not shown on the graphs. T-tests
were used to support qualitative analysis of CBA-generated cytokine data.
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Francisella research and further underscore the need for
immunotherapeutic studies in both A and B subtypes.
Finally, we would like to assert that all research was
conducted in compliance with the Animal Welfare Act
and other federal statutes and regulations relating to
animals and experiments involving animals and adheres
to principles stated in the Guide for the Care and Use
of Laboratory Animals, National Research Council,
1996. The facility where this research was conducted is
fully accredited by the Association for Assessment and
Accreditation of Laboratory Animal Care International.
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